KC

Kamal Chandra

Active Director Director DIN 08767020
DIN 08767020 First appointment Aug 2020 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2020
Shareholding value •••• Premium profile

About Kamal Chandra

Data last updated:

Kamal Chandra is a Director at Seamus Pharmaceuticals Private Limited (since 2020). The company operates in Chemicals. Seamus Pharmaceuticals Private Limited reported revenue of ₹97.9 Lakh (FY 2024).

DIN 08767020
Primary Designation Director
Industry Chemicals
First Appointment 03 Aug 2020
Oldest Company Age 6 yrs
Largest company Seamus Pharmaceuticals Private Limited · ₹97.9 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Aug 20202020₹97.9 Lakh (FY 2024)Active

Board colleagues of Kamal Chandra

Directorship timeline

Open interactive timeline →
Seamus Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Kamal Chandra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kamal Chandra

Kamal Chandra currently holds 1 directorship: Seamus Pharmaceuticals Private Limited (Director, since 03 Aug 2020, revenue ₹97.9 Lakh (FY 2024)).

Kamal Chandra was first appointed on 03 Aug 2020 as Director at Seamus Pharmaceuticals Private Limited.

The current boards of Kamal Chandra's companies include Shreshtha Venktesh (Seamus Pharmaceuticals Private Limited), Suraj Singh Chauhan (Seamus Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available